EA201792417A1 - Лиофилизированный фармацевтический состав рифабутина и способ его получения - Google Patents

Лиофилизированный фармацевтический состав рифабутина и способ его получения

Info

Publication number
EA201792417A1
EA201792417A1 EA201792417A EA201792417A EA201792417A1 EA 201792417 A1 EA201792417 A1 EA 201792417A1 EA 201792417 A EA201792417 A EA 201792417A EA 201792417 A EA201792417 A EA 201792417A EA 201792417 A1 EA201792417 A1 EA 201792417A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rifabutin
pharmaceutical composition
lyophylized
preparation
discloses
Prior art date
Application number
EA201792417A
Other languages
English (en)
Inventor
Митеш Натаварлал Пател
Мафатлал Трибховандас Даве
Пранавкумар Джаиеш Чокси
Original Assignee
Гуфик Байосайенсиз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гуфик Байосайенсиз Лимитед filed Critical Гуфик Байосайенсиз Лимитед
Publication of EA201792417A1 publication Critical patent/EA201792417A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В настоящем изобретении раскрыт лиофилизированный фармацевтический состав рифабутина вместе с подходящим солюбилизирующим агентом и объемообразующим агентом для парентерального введения, который обеспечивает достаточную солюбилизацию и стабилизацию рифабутина, улучшая тем самым срок годности, и снижает вероятность осаждения при хранении. В изобретении также раскрыт способ получения указанного фармацевтического состава.
EA201792417A 2015-05-04 2015-09-07 Лиофилизированный фармацевтический состав рифабутина и способ его получения EA201792417A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1770MU2015 2015-05-04
PCT/IN2015/000348 WO2016178240A1 (en) 2015-05-04 2015-09-07 A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof

Publications (1)

Publication Number Publication Date
EA201792417A1 true EA201792417A1 (ru) 2018-04-30

Family

ID=57218191

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792417A EA201792417A1 (ru) 2015-05-04 2015-09-07 Лиофилизированный фармацевтический состав рифабутина и способ его получения

Country Status (3)

Country Link
EP (1) EP3291798A4 (ru)
EA (1) EA201792417A1 (ru)
WO (1) WO2016178240A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022004659A2 (pt) * 2019-09-12 2022-06-21 BioVersys AG Métodos de tratamento com rifabutina, usos e composições
US11344537B2 (en) 2019-09-18 2022-05-31 BioVersys AG Rifabutin treatment methods, uses, and compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005065185A2 (en) * 2003-12-24 2005-07-21 Collegium Pharmaceuticals, Inc. Temperature-stable formulations, and methods of development thereof
RU2327457C1 (ru) * 2007-06-26 2008-06-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Лекарственное средство на основе рифабутина, препарат противомикробного действия, содержащий наночастицы, и способ его получения
CA2714043C (en) * 2008-02-08 2016-11-08 Giaconda Limited Methods and compositions for treating inflammatory bowel disease
EA013569B1 (ru) * 2009-02-24 2010-06-30 Ооо "Научно-Производственный Комплекс "Наносистема"" Фармацевтическая композиция рифабутина для лечения туберкулеза и заболеваний, опосредованных helicobacter pylori, способ ее получения и способ лечения

Also Published As

Publication number Publication date
WO2016178240A1 (en) 2016-11-10
EP3291798A1 (en) 2018-03-14
EP3291798A4 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
CY1122038T1 (el) Ετεροδιλειτουργικοι αναστολεις των ε-σελεκτινων και των υποδοχεων χημειοκινης cxcr4
MX2018003306A (es) Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
MY191574A (en) Pharmaceutical compositions comprising meloxicam
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2019003095A (es) Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk.
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
AR102085A1 (es) Composición nutricional para el entorno gastrointestinal para la provisión de un perfil metabólico y microbioma mejorados
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
EA201591758A8 (ru) Подкожное введение adamts13
MY176618A (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)- n,2-dimethylbenzofuran-3-carboxamide
WO2016001905A3 (en) Stable liquid ready-to-use injectable formulation of bortezomib
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
EA201792417A1 (ru) Лиофилизированный фармацевтический состав рифабутина и способ его получения
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
NZ733451A (en) Combination therapy for pulmonary hypertension
MX2019014666A (es) Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo.
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
MX2017013879A (es) Composiciones que comprenden anakinra.